433
Participants
Start Date
February 28, 2006
Primary Completion Date
June 30, 2007
Study Completion Date
December 31, 2007
Moxifloxacin (with rifampin, pyrazinamide, and ethambutol)
Moxifloxacin 400mg daily, 8 weeks
isoniazid
isoniazid, oral, 300 mg, daily, 8 weeks
Columbia University, New York
Harlem Hospital, Columbia University, New York
Washington DC Veterans Administration Medical Center, Washington D.C.
Johns Hopkins University School of Medicine, Baltimore
Duke University Medical Center, Durham
Emory University School of Medicine, Atlanta
Veterans Administration Tennessee Valley Health Care System, Nashville
Hines Veterans Administration Medical Center, Hines
Northwestern University, Chicago
Veterans Administration Medical Center of Arkansas, Little Rock
University of North Texas Health Science Center, Fort Worth
Houston Veterans Administration Medical Center, Houston
Audie L Murphy Memorial Veterans Administration Medical Center, San Antonio
Denver Public Health Department, Denver
University of Southern California Medical Center, Los Angeles
University of California at San Diego, San Diego
University of California, San Francincisco, San Francisco
Seattle-King County Health Department, Seattle
Boston University Medical Center, Boston
New Jersey School of Medicine, Newark
Hopital Universitario Clementino Fraga Filho, Rio de Janeiro
University of Manitoba, Winnepeg
Montreal Chest Institute, Montreal
Nelson R. Mandela School of Medicine, Durban
Makerere University Medical School, Kampala
Agencia de Salut Publica, Barcelona
Collaborators (1)
Global Alliance for TB Drug Development
OTHER
Bayer
INDUSTRY
Centers for Disease Control and Prevention
FED